Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.920
+0.100 (2.07%)
Jun 29, 2026, 1:38 PM EDT - Market open
Alterity Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Alterity Therapeutics stock have an average target of 11, with a low estimate of 10 and a high estimate of 12. The average target predicts an increase of 123.58% from the current stock price of 4.92.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alterity Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 1 | 0 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 2 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Ladenburg Thalmann & Co. No rating | Ladenburg Thalmann & Co. | Buy Initiates $10 | Buy | Initiates | $10 | +103.25% | Jun 16, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $12 | Buy | Reiterates | $12 | +143.90% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
3.53M
from 5.44M
Decreased by -35.11%
Revenue Next Year
1.65M
from 3.53M
Decreased by -53.27%
EPS This Year
-2.58
EPS Next Year
-2.58
from -2.58
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.8M | 4.9M | |
| Avg | 3.5M | 1.6M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.4% | 40.2% | |
| Avg | -35.1% | -53.3% | |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -2.58 | -2.58 | |
| Low | -5.15 | -5.15 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.